GO:0006783 heme biosynthetic process: Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0006783 (heme biosynthetic process) describes the chemical reactions and pathways that build heme, an iron-containing porphyrin ring, from simpler precursors.
• Heme is essential for oxygen transport, electron transfer, and catalysis, and it also acts as a multifunctional regulator of gene expression and cellular metabolism [1,8].
• The pathway is highly conserved but has a convoluted evolutionary history, with different organisms using alternative routes and intermediates.
• Key enzymes include ALAS1/ALAS2, ALAD, HMBS, UROS, UROD, CPOX, PPOX, and FECH, which catalyze the stepwise conversion of glycine and succinyl-CoA to heme.
• Defects in heme biosynthesis cause porphyrias and contribute to erythropoietic and neurological disorders, making the pathway a target for experimental modeling.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models enable causal testing of heme biosynthesis genes in disease and development.
Description
Heme biosynthetic process (GO:0006783) is the biological process that produces heme, an iron complexed within a porphyrin (tetrapyrrole) ring, from less complex precursors. Heme is best known as the prosthetic group of haemoglobins and other oxygen-binding haem proteins, where it enables reversible oxygen binding and transport [1,3]. Beyond oxygen transport, heme is a cofactor for cytochromes, catalases, peroxidases, and nitric oxide synthases, and it participates in electron transfer and oxidative chemistry [1,3]. The pathway is therefore central to respiration, detoxification, and cellular signaling. Heme also functions as a multifunctional regulator, influencing transcription, translation, and protein stability. In erythropoiesis, heme synthesis is tightly coordinated with globin production to ensure efficient hemoglobin assembly. Because heme is essential yet potentially toxic when free, its biosynthesis is spatially and temporally regulated, with intermediates and end products acting as feedback signals [4,8]. Researchers study GO:0006783 to understand mitochondrial and cytosolic enzymology, iron metabolism, and the molecular basis of porphyrias and other heme-related diseases [4,5]. The pathway also intersects with mitochondrial-ER contact sites that supply iron for heme and iron-sulfur cluster synthesis. This article integrates the QuickGO definition with verified literature to outline the mechanism, key genes, disease links, and experimental strategies for investigating heme biosynthetic process.
heme biosynthetic process At A Glance
| GO ID | GO:0006783 |
|---|---|
| GO term | heme biosynthetic process |
| Ontology | biological_process |
| Synonym | haem biosynthesis; haem biosynthetic process; heme anabolism; heme biosynthesis; heme formation; heme synthesis |
| Definition | The chemical reactions and pathways resulting in the formation of heme, any compound of iron complexed in a porphyrin (tetrapyrrole) ring, from less complex precursors. |
| Major function | Production of heme for oxygen transport, electron transfer, catalysis, and regulatory roles [1,8] |
| Subcellular location | Mitochondrion and cytosol; enzymes are partitioned between compartments |
| Key intermediates | 5-aminolevulinic acid, porphobilinogen, hydroxymethylbilane, uroporphyrinogen III, coproporphyrinogen III, protoporphyrin IX |
| Related processes | Iron homeostasis, erythropoiesis, mitochondrial metabolism, porphyrin metabolism [2,5] |
What Is GO:0006783?
GO:0006783 heme biosynthetic process is defined as the chemical reactions and pathways resulting in the formation of heme, any compound of iron complexed in a porphyrin (tetrapyrrole) ring, from less complex precursors. In practice, this process encompasses the stepwise enzymatic conversion of glycine and succinyl-CoA through porphyrin intermediates to protoporphyrin IX, followed by insertion of ferrous iron to yield heme. The term is a biological process in the Gene Ontology and includes both the canonical pathway and organism-specific variations documented in the literature.
Why Is heme biosynthetic process Important in Cell Biology?
Heme biosynthetic process is essential because heme is required for fundamental biological functions, including oxygen transport by haemoglobins, electron transfer in cytochromes, and catalysis by haem enzymes [1,3]. Disruption of the pathway leads to accumulation of toxic intermediates and to diseases such as porphyrias, and it impairs erythropoiesis and mitochondrial function [4,5]. Heme also acts as a signaling molecule that regulates gene expression and cellular differentiation, linking metabolism to transcriptional control. Understanding GO:0006783 therefore has broad implications for hematology, neurology, cancer biology, and metabolic engineering.
• Heme is the prosthetic group of haemoglobins and myoglobin, enabling oxygen transport and storage.
• Haem proteins catalyze diverse reactions, including electron transfer and oxygen activation.
• Heme serves as a multifunctional regulator of transcription, translation, and protein stability.
• The pathway is essential for erythropoiesis, where heme synthesis must match globin production.
• Defects in heme biosynthesis cause porphyrias and contribute to neurological and hepatic dysfunction.
• Mitochondria-ER contacts provide iron for heme and iron-sulfur cluster biosynthesis.
• Heme biosynthesis is evolutionarily ancient but shows lineage-specific variations.
• The pathway is a target for antimicrobial and anticancer strategies because of its essentiality.
• CRISPR screens can identify modifiers of heme biosynthesis and heme-dependent processes.
• Heme biosynthesis intersects with iron metabolism, oxidative stress, and mitochondrial quality control [2,5].
What Happens During heme biosynthetic process?
Stage 1: Synthesis of 5-aminolevulinic acid (ALA)
In simple terms: The pathway starts by making a small molecule called ALA, which is the first committed building block of heme.
In animals, the first step of heme biosynthesis is the condensation of glycine and succinyl-CoA to form 5-aminolevulinic acid (ALA), catalyzed by ALA synthase (ALAS1 in non-erythroid cells and ALAS2 in erythroid cells) in the mitochondrial matrix. This reaction requires pyridoxal phosphate as a cofactor and is the rate-limiting step of the pathway. In plants, algae, and many bacteria, ALA is synthesized via the C5 pathway from glutamate, illustrating the evolutionary diversity of heme biosynthesis. The enzyme ALAS is regulated by heme at multiple levels, including feedback inhibition and repression of gene expression.
Stage 2: Formation of porphobilinogen and hydroxymethylbilane
In simple terms: ALA molecules are joined together to build larger ring-like molecules that will become the porphyrin core.
Two molecules of ALA are condensed by ALA dehydratase (ALAD, also known as porphobilinogen synthase) to form porphobilinogen (PBG) in the cytosol. Four molecules of PBG are then polymerized by hydroxymethylbilane synthase (HMBS, also called PBG deaminase) to form the linear tetrapyrrole hydroxymethylbilane. This step is important because defects in ALAD or HMBS cause specific porphyrias. The reaction sequence is conserved across most heme-synthesizing organisms, although the enzymes may differ in structure and regulation.
Stage 3: Cyclization and modification of the porphyrin ring
In simple terms: The linear molecule is closed into a ring and then chemically modified to reach the correct porphyrin structure.
Hydroxymethylbilane is cyclized by uroporphyrinogen III synthase (UROS) to form uroporphyrinogen III, the first cyclic tetrapyrrole in the pathway. Uroporphyrinogen III is then decarboxylated by uroporphyrinogen decarboxylase (UROD) to yield coproporphyrinogen III. Coproporphyrinogen III is transported into the mitochondrion and oxidized by coproporphyrinogen oxidase (CPOX) to protoporphyrinogen IX. Protoporphyrinogen IX is further oxidized by protoporphyrinogen oxidase (PPOX) to protoporphyrin IX. These oxidative steps are oxygen-dependent and occur in the mitochondrial intermembrane space or inner membrane.
Stage 4: Iron insertion to form heme
In simple terms: The final step inserts an iron atom into the porphyrin ring to make mature heme.
The final step of heme biosynthesis is the insertion of ferrous iron (Fe2+) into protoporphyrin IX, catalyzed by ferrochelatase (FECH) on the inner mitochondrial membrane. This reaction requires reducing conditions and is coupled to iron availability. Mitochondria-ER contact sites have been implicated in supplying iron for heme and iron-sulfur cluster synthesis, highlighting the integration of heme biosynthesis with cellular iron homeostasis. The product, heme, is then transported to the cytosol and other compartments or incorporated into hemoproteins.
Stage 5: Regulation and coordination with globin synthesis
In simple terms: The pathway is turned up or down to match the cell's need for heme, especially during red blood cell development.
Heme biosynthesis is tightly regulated to avoid accumulation of toxic intermediates. In erythroid cells, ALAS2 expression is induced by erythropoietin and coordinated with globin synthesis to ensure balanced hemoglobin production. Heme itself regulates the pathway by feedback inhibition of ALAS and by controlling the translation of ALAS2 mRNA through the iron-responsive element (IRE) system. In non-erythroid cells, ALAS1 is regulated by heme and by circadian and metabolic signals. The pathway also responds to iron availability, with mitochondrial-ER contacts playing a role in iron supply.
Key Genes Involved in GO:0006783 heme biosynthetic process
The following genes encode enzymes and regulators that carry out or control heme biosynthetic process (GO:0006783).
| Gene | Major Role | Research Relevance |
|---|---|---|
| ALAS1 | First enzyme of heme biosynthesis in non-erythroid cells; condenses glycine and succinyl-CoA to ALA | Regulated by heme and xenobiotics; target for porphyria and metabolic studies [4,8] |
| ALAS2 | Erythroid-specific ALA synthase; rate-limiting for heme synthesis in red blood cells | Mutations cause X-linked sideroblastic anemia; key for erythropoiesis research |
| ALAD | Condenses two ALA molecules to porphobilinogen | Deficiency causes ALAD porphyria; environmental toxin target |
| HMBS | Polymerizes four PBG molecules to hydroxymethylbilane | Defects cause acute intermittent porphyria |
| UROS | Cyclizes hydroxymethylbilane to uroporphyrinogen III | Mutations cause congenital erythropoietic porphyria |
| UROD | Decarboxylates uroporphyrinogen III to coproporphyrinogen III | Deficiency causes porphyria cutanea tarda and hepatoerythropoietic porphyria |
| CPOX | Oxidizes coproporphyrinogen III to protoporphyrinogen IX | Mutations cause hereditary coproporphyria |
| PPOX | Oxidizes protoporphyrinogen IX to protoporphyrin IX | Defects cause variegate porphyria |
| FECH | Inserts ferrous iron into protoporphyrin IX to form heme | Mutations cause erythropoietic protoporphyria |
| GATA1 | Transcription factor that regulates erythroid genes including ALAS2 and globins | Essential for erythropoiesis and heme synthesis coordination |
| IRP1/IRP2 (ACO1/IREB2) | Iron regulatory proteins that control ALAS2 translation via IRE | Link iron status to heme biosynthesis |
| SLC25A38 | Mitochondrial glycine transporter; supports ALA synthesis in erythroid cells | Mutations cause sideroblastic anemia |
| ABCB6 | Mitochondrial transporter implicated in porphyrin transport | Candidate modifier of heme biosynthesis |
| ABCB10 | Mitochondrial transporter that interacts with FECH and supports heme synthesis | Required for erythropoiesis; potential disease modifier |
| CLPX | Mitochondrial protease that regulates ALAS stability | Modulates heme biosynthesis in erythroid cells |
| SUCLA2 | Succinyl-CoA ligase subunit; supplies succinyl-CoA for ALA synthesis | Links TCA cycle to heme biosynthesis |
| PPOX and CPOX cofactors | Oxygen-dependent oxidases requiring FAD | Targets for inhibitor and mechanism studies |
| Heme-regulated eIF2alpha kinase (HRI/EIF2AK1) | Kinase that coordinates globin and heme synthesis via translation control | Important for erythroid proteostasis |
How Is heme biosynthetic process Regulated?
Heme biosynthetic process is regulated at multiple levels to balance heme supply with demand and to prevent toxicity. The first enzyme, ALAS, is feedback-inhibited by heme and its expression is repressed by heme in non-erythroid cells. In erythroid cells, ALAS2 translation is controlled by iron regulatory proteins (IRP1/IRP2) through an iron-responsive element in its mRNA, linking heme synthesis to iron availability. Erythropoietin signaling and the transcription factor GATA1 induce erythroid genes, including ALAS2 and globin genes, to coordinate heme and globin production. Mitochondrial-ER contact sites contribute to iron supply for heme and iron-sulfur cluster synthesis, integrating heme biosynthesis with mitochondrial metabolism. Additionally, the heme-regulated eIF2alpha kinase (HRI) coordinates globin translation with heme availability to prevent proteotoxic stress in erythroid cells.
heme biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ALAS2 | X-linked sideroblastic anemia | Knockout or point-mutation in erythroid cell lines; knock-in of patient mutations |
| HMBS | Acute intermittent porphyria | Hepatocyte knockout or knockdown; overexpression of wild-type vs mutant |
| UROD | Porphyria cutanea tarda | Liver-specific knockout; knock-in of UROD mutations |
| FECH | Erythropoietic protoporphyria | Knockout in erythroid cells; knock-in of FECH mutations |
| SLC25A38 | Sideroblastic anemia | Knockout in hematopoietic stem cells; rescue with wild-type |
Porphyrias: inherited defects in heme biosynthesis
The porphyrias are a group of disorders caused by partial deficiencies in enzymes of heme biosynthesis, leading to accumulation of toxic porphyrin intermediates. Acute intermittent porphyria results from HMBS deficiency and presents with neurovisceral attacks. Porphyria cutanea tarda is associated with UROD deficiency and causes photosensitive skin lesions. Erythropoietic protoporphyria is due to FECH deficiency and leads to painful photosensitivity. Congenital erythropoietic porphyria is caused by UROS deficiency and results in severe skin blistering and anemia. Hereditary coproporphyria and variegate porphyria are caused by CPOX and PPOX deficiencies, respectively. These disorders highlight the importance of each enzymatic step and the need for accurate genetic models.
Sideroblastic anemia and iron metabolism
X-linked sideroblastic anemia is caused by mutations in ALAS2, leading to impaired heme synthesis in erythroid precursors and mitochondrial iron accumulation. Mutations in SLC25A38, a mitochondrial glycine transporter, also cause sideroblastic anemia by limiting ALA synthesis. The coordination between heme biosynthesis and iron metabolism is further emphasized by the role of mitochondrial-ER contact sites in iron supply. These conditions illustrate how defects in heme biosynthesis can disrupt erythropoiesis and iron homeostasis.
Neurological and hepatic manifestations
Acute porphyrias can cause life-threatening neurological attacks, including abdominal pain, neuropathy, and seizures, due to the neurotoxicity of ALA and porphobilinogen. Hepatic complications, including hepatocellular carcinoma, are associated with acute intermittent porphyria. The liver is a major site of heme biosynthesis, and ALAS1 is induced by drugs and other xenobiotics, which can precipitate attacks. Understanding the regulation of heme biosynthesis in the liver is therefore clinically important.
Heme biosynthesis in cancer and other diseases
Altered heme biosynthesis has been observed in cancer, where heme is required for mitochondrial respiration and antioxidant defense. Heme also regulates gene expression and cell differentiation, and its dysregulation may contribute to metabolic reprogramming in tumors. In addition, heme biosynthesis is essential for many pathogens, making it a potential target for antimicrobial therapy. These broad roles underscore the importance of GO:0006783 in human health and disease.
From heme biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene required for heme biosynthesis? | CRISPR knockout in erythroid or hepatic cell lines |
| Does a specific patient mutation impair enzyme function? | CRISPR point mutation knock-in of the variant |
| Can a tagged enzyme be used to study localization and interactions? | CRISPR knock-in of an epitope tag (e.g., FLAG, HA) |
| Does overexpression of a gene increase heme production? | CRISPR activation or cDNA overexpression |
| Which genes modify heme biosynthesis under stress? | Genome-wide CRISPR knockout or activation screen |
| How does iron availability affect heme synthesis? | Knockout of iron transporters or mitochondrial-ER contact proteins |
How to Study the heme biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss of gene function | Test requirement of a gene for heme biosynthesis |
| CRISPR point mutation | Specific amino acid change | Model patient mutations in enzymes |
| CRISPR knock-in | Tagged or reporter gene | Study localization and dynamics |
| RNA-seq | Transcript abundance | Measure pathway gene expression |
| Ribo-seq | Translation efficiency | Assess ALAS2 translation control |
| LC-MS metabolomics | Porphyrin intermediates | Quantify pathway flux |
| Enzyme activity assays | Catalytic activity | Diagnose enzyme deficiencies |
| Proximity labeling | Protein interactome | Identify regulators and partners |
Genetic and genomic methods
CRISPR-Cas9 knockout, point-mutation knock-in, and overexpression models are powerful for dissecting heme biosynthesis genes [4,5]. RNA-seq and ribosome profiling (Ribo-seq) can measure transcript and translation changes in response to heme demand or iron status. Genome-wide CRISPR screens can identify modifiers of heme biosynthesis and heme-dependent growth.
Biochemical and metabolomic methods
Heme and porphyrin intermediates can be quantified by HPLC, LC-MS, or spectrophotometric assays. Enzyme activities of ALAS, ALAD, HMBS, UROS, UROD, CPOX, PPOX, and FECH can be measured in cell lysates or mitochondria. Iron insertion by FECH can be assayed using protoporphyrin IX and ferrous iron.
Imaging and subcellular localization
Fluorescently tagged enzymes or heme sensors can be used to visualize heme biosynthesis in live cells. Mitochondrial-ER contact sites can be imaged to study iron transfer for heme synthesis. Super-resolution microscopy can resolve the distribution of enzymes between mitochondria and cytosol.
Proteomic and interactomic methods
Affinity purification coupled to mass spectrometry can identify protein-protein interactions of heme biosynthesis enzymes. Proximity labeling (BioID, APEX) can map the interactome of mitochondrial and cytosolic enzymes. These approaches help define the assembly and regulation of the pathway.
How CRISPR Can Be Used to Study GO:0006783 heme biosynthetic process
Knockout
CRISPR knockout of heme biosynthesis genes (e.g., ALAS1, ALAS2, FECH) can be used to create isogenic cell models that lack specific enzymatic steps. These models are valuable for studying the consequences of pathway blockade, including intermediate accumulation and compensatory responses. Knockout of ALAS2 in erythroid cells impairs hemoglobinization and can model sideroblastic anemia.
Point Mutation
CRISPR point mutation knock-in allows precise introduction of patient-derived missense mutations into endogenous loci. This is particularly useful for porphyria-associated variants in HMBS, UROD, CPOX, PPOX, and FECH, enabling functional assessment of enzyme activity and stability. Point mutations can also be used to dissect catalytic residues and regulatory phosphorylation sites.
Knock-in
CRISPR knock-in of epitope tags, fluorescent proteins, or reporters into heme biosynthesis genes enables real-time tracking of protein localization and turnover. Tagged FECH or ALAS2 can be used to study mitochondrial import and assembly. Knock-in of a heme-responsive reporter can provide a readout of pathway activity.
Overexpression
CRISPR activation (CRISPRa) or cDNA overexpression can increase expression of heme biosynthesis genes to boost heme production. Overexpression of ALAS2 or FECH may enhance heme synthesis in engineered cells for bioproduction or therapeutic applications. Conversely, overexpression can be used to test gain-of-function effects and feedback regulation.
How EDITGENE Supports heme biosynthetic process Research
Researchers studying heme biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in pathway regulation, disease pathogenesis, or metabolic adaptation. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for heme biosynthetic process research.
Frequently Asked Questions About heme biosynthetic process
What is GO:0006783 heme biosynthetic process?
GO:0006783 is the Gene Ontology term for the biological process that produces heme, an iron-containing porphyrin, from simpler precursors through a series of enzymatic steps.
What genes are involved in heme biosynthetic process?
Key genes include ALAS1, ALAS2, ALAD, HMBS, UROS, UROD, CPOX, PPOX, and FECH, which encode the enzymes of the pathway.
Where does heme biosynthesis occur in the cell?
The pathway starts and ends in the mitochondrion, with intermediate steps occurring in the cytosol.
What is the first step of heme biosynthesis?
The first step is the condensation of glycine and succinyl-CoA to form 5-aminolevulinic acid, catalyzed by ALA synthase.
How is heme biosynthesis regulated?
It is regulated by heme feedback inhibition of ALAS, by iron-responsive translation control of ALAS2, and by erythroid transcription factors such as GATA1 [5,8].
What diseases are associated with defects in heme biosynthesis?
Defects cause porphyrias, sideroblastic anemia, and other disorders affecting the skin, nervous system, and liver [4,5].
What is the role of ferrochelatase in heme synthesis?
Ferrochelatase (FECH) inserts ferrous iron into protoporphyrin IX to form heme in the final step of the pathway.
How can CRISPR be used to study heme biosynthesis?
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of heme biosynthesis genes in disease and metabolism [4,5].
Why is heme biosynthesis important for erythropoiesis?
Erythroid cells require large amounts of heme for hemoglobin, and heme synthesis is coordinated with globin production to ensure efficient red blood cell formation.
What are the toxic intermediates in heme biosynthesis?
Intermediates such as ALA and porphobilinogen can be neurotoxic when they accumulate, as seen in acute porphyrias.
Conclusion
Heme biosynthetic process (GO:0006783) is a fundamental metabolic pathway that produces heme, a molecule essential for oxygen transport, electron transfer, catalysis, and cellular regulation [1,8]. The pathway involves eight enzymatic steps distributed between mitochondria and cytosol, and its dysfunction causes porphyrias, sideroblastic anemia, and other disorders [4,5]. Advances in CRISPR-based genome editing enable precise functional studies of heme biosynthesis genes, from knockout and point mutations to knock-in reporters and overexpression. These approaches, combined with metabolomics and proteomics, will continue to illuminate the regulation and disease relevance of heme biosynthesis.
References
- 1. Gell DA. 2018. Structure and function of haemoglobins.. Blood Cells Mol Dis 70:13-42 PMID: 29126700
- 2. Oshio H et al.. 2026. Mitochondria-ER contacts function as an iron supply hub.. Nat Cell Biol 28(7):1464-1479 PMID: 42270976
- 3. Wilson MT et al.. 2008. Oxygen-binding haem proteins.. Exp Physiol 93(1):128-32 PMID: 17981931
- 4. Kořený L et al.. 2022. The convoluted history of haem biosynthesis.. Biol Rev Camb Philos Soc 97(1):141-162 PMID: 34472688
- 5. Chiabrando D et al.. 2014. Heme and erythropoieis: more than a structural role.. Haematologica 99(6):973-83 PMID: 24881043
- 8. Padmanaban G et al.. 1989. Haem as a multifunctional regulator.. Trends Biochem Sci 14(12):492-6 PMID: 2696180
